MX2023009414A - Metodos para detectar una cadena ligera de neurofilamento en plasma y fluido cefalorraquideo. - Google Patents

Metodos para detectar una cadena ligera de neurofilamento en plasma y fluido cefalorraquideo.

Info

Publication number
MX2023009414A
MX2023009414A MX2023009414A MX2023009414A MX2023009414A MX 2023009414 A MX2023009414 A MX 2023009414A MX 2023009414 A MX2023009414 A MX 2023009414A MX 2023009414 A MX2023009414 A MX 2023009414A MX 2023009414 A MX2023009414 A MX 2023009414A
Authority
MX
Mexico
Prior art keywords
methods
cerebrospinal fluid
plasma
detecting
light chain
Prior art date
Application number
MX2023009414A
Other languages
English (en)
Inventor
David Holtzman
Hong Jiang
Melissa Budelier
Randall Bateman
Original Assignee
Washington University St Louis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University St Louis filed Critical Washington University St Louis
Publication of MX2023009414A publication Critical patent/MX2023009414A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • External Artificial Organs (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente divulgación proporciona métodos para detectar y opcionalmente cuantificar Nfl presente en el líquido cefalorraquídeo y la sangre y el uso de los métodos para detectar y opcionalmente medir niveles de biomarcadores de Nfl indicativos de daño neuronal. También se describen anticuerpos anti-Nfl.
MX2023009414A 2021-02-10 2022-02-10 Metodos para detectar una cadena ligera de neurofilamento en plasma y fluido cefalorraquideo. MX2023009414A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163147833P 2021-02-10 2021-02-10
US202163183417P 2021-05-03 2021-05-03
US202163197826P 2021-06-07 2021-06-07
PCT/US2022/015998 WO2022173965A1 (en) 2021-02-10 2022-02-10 Methods for detecting neurofilament light chain in plasma and cerebrospinal fluid

Publications (1)

Publication Number Publication Date
MX2023009414A true MX2023009414A (es) 2023-10-26

Family

ID=82837306

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009414A MX2023009414A (es) 2021-02-10 2022-02-10 Metodos para detectar una cadena ligera de neurofilamento en plasma y fluido cefalorraquideo.

Country Status (12)

Country Link
EP (1) EP4291892A1 (es)
JP (1) JP2024507755A (es)
KR (1) KR20230154307A (es)
AU (1) AU2022220697A1 (es)
BR (1) BR112023015991A2 (es)
CA (1) CA3207924A1 (es)
CL (1) CL2023002353A1 (es)
CO (1) CO2023011971A2 (es)
CR (1) CR20230441A (es)
IL (1) IL305068A (es)
MX (1) MX2023009414A (es)
WO (1) WO2022173965A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117164711B (zh) * 2023-09-28 2024-01-30 北京凯祥弘康生物科技有限公司 一种抗神经纤维丝轻链蛋白的抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053723A1 (en) * 2007-08-24 2009-02-26 Shangxi Xiao Peripherin and Neurofilament Light Protein Splice Variants in Amyotrophic Lateral Sclerosis (ALS)
US20170315136A9 (en) * 2009-06-19 2017-11-02 Banyan Biomarkers, Inc. Biomarker assay of neurological condition

Also Published As

Publication number Publication date
CR20230441A (es) 2023-11-10
KR20230154307A (ko) 2023-11-07
AU2022220697A1 (en) 2023-09-21
CA3207924A1 (en) 2022-08-18
CO2023011971A2 (es) 2023-09-29
JP2024507755A (ja) 2024-02-21
WO2022173965A1 (en) 2022-08-18
BR112023015991A2 (pt) 2024-01-02
EP4291892A1 (en) 2023-12-20
IL305068A (en) 2023-10-01
CL2023002353A1 (es) 2024-03-08

Similar Documents

Publication Publication Date Title
ES2570380T3 (es) Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
CO6680668A2 (es) Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor
WO2013093635A3 (en) Plasma micrornas for the detection of early colorectal cancer
CL2009002114A1 (es) Un método para detectar al menos un olor en una muestra de gas que comprende: reducir, al menos parcialmente, una cantidad de agua en la muestra de gas; y detectar la presencia o ausencia de olor en la muestra; se describe además un aparato para detectar y/o medir olores en una muestra de gas.
ES2721907T3 (es) Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
MX366275B (es) Metodos para detectar y medir la agregacion.
EA201490046A1 (ru) Мониторинг трубопроводов
EA201270608A1 (ru) Способ и устройство для измерения расхода в газопроводах или нефтепроводах
MY182409A (en) Surface inspection method and surface inspection apparatus
EA201101563A1 (ru) Безколбовый спектрометр
MX2019002578A (es) Métodos de detección de la expresión del ligando 1 de muerte programada por célula y usos de los mismos.
MY176182A (en) Biosensor based on measurements of the clustering dynamics of magnetic particles
PE20141450A1 (es) Ensayo de lisiloxidasa-homologo 2 y metodos de uso del mismo
CL2023002353A1 (es) Métodos para detectar una cadena ligera de neurofilamento en plasma y fluido cefalorraquídeo
BR112014031319A2 (pt) aparelho de teste de vazamento e método de teste de vazamento
WO2014096942A3 (es) Herramienta inteligente para la detección de perforaciones, cascotas y abolladuras en tuberías de transporte
BR112014002108A8 (pt) sistema e método para inspecionar uma tubulação submarina
MX348655B (es) Biomarcadores para pronosticar sensibilidad a tratamientos contra el cancer.
BR112018009435A2 (pt) detecção de vazamento com oxigênio
BR112016013976A2 (pt) método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método
WO2014165003A8 (en) Systems and methods for fluid analysis using electromagnetic energy
CA3056911A1 (en) Methods for diagnosing and treating inflammatory bowel disease
MX2015013993A (es) Procedimientos y series para su uso en los mismos.
FR2971846B1 (fr) Procede d'observation d'un echantillon